Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces SMX's unveiling of a four-layer Digital Material Passport Platform (DMPP) for plastics, representing a significant product launch and strategic milestone. The disclosure describes the company's new integrated platform connecting physical plastic marking, digital passports, market trading infrastructure, and circularity credits. While this is a material operational and strategic development for the company's business, it does not fit neatly into the specific event categories (it is not M&A, earnings, executive changes, debt issuance, or other defined types). The announcement of a major new product platform and the opening of a global client experience with free trials constitutes a material operational event that would affect a reasonable investor's assessment of the company's strategic direction and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
Draganfly announced its selection as a Qualified Supplier under Canada's Defence Drone Initiative Marketplace across all five capability streams, effective August 28, 2026. This is a material operational and strategic milestone that establishes a pathway for significant government contract opportunities with the Canadian Armed Forces and Coast Guard within a $180 billion defence procurement program. The qualification across all five streams positions the company to compete for substantial future defence contracts, making this a material business development event that would affect a reasonable investor's assessment of the company's growth prospects and market access.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 1.01
StimCell Energetics entered into an Advisory Services Agreement with Stonegate Capital Markets on August 24, 2026, to identify and introduce prospective investors and strategic counterparties for potential transactions involving the Company's assets, debt, or equity securities. The engagement is a strategic advisory arrangement for capital-raising and M&A support on a best-efforts, non-exclusive basis with success-based compensation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
X4 Pharmaceuticals announced a positive outcome from an FDA Type C Meeting regarding the 4WARD Phase 3 clinical trial for mavorixafor in chronic neutropenia. The FDA agreed to reduce the trial's sample size from 176 to 126 participants while maintaining statistical power for co-primary endpoints, and approved the proposed safety database for a potential supplemental new drug application. This is a material regulatory milestone affecting the clinical development pathway and timeline (enrollment expected by end-2026, topline data in H1 2028) for a key product candidate, making it a significant operational/strategic event for the company's pipeline, though it does not fit neatly into the specific event categories (not a restatement, impairment, covenant breach, or other defined type).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
Harmony reports a fatal workplace incident at its Moab Khotsong mine on September 6, 2026, involving a seismicity-related loss of life. While the disclosure is primarily operational and safety-related rather than fitting a specific named category, it is material to investors as it reflects operational risk, potential regulatory consequences, and management's commitment to safety—factors that affect the registrant's ability to operate its mines safely and profitably. The incident triggers an investigation by the Department of Mineral and Petroleum Resources, adding regulatory dimension.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 8.01
Strive announced a bitcoin purchase of 1,375 BTC at ~$79,281 per coin (totaling approximately $109 million) during August 31–September 4, 2026, along with updated holdings of cash, bitcoin, and equity securities. This represents a material capital deployment and treasury strategy execution that would affect investor assessment of the company's financial position and strategic direction, but does not fit neatly into debt issuance, M&A, impairment, or other specific financial categories. The disclosure is operational/strategic in nature—a treasury management and asset allocation decision—rather than a discrete financial event like a debt or equity issuance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Cycurion announced approximately $800,000 in annual contract spend across multiple new commercial engagements, including a pharmaceutical AI Center of Excellence engagement and a NACCHO award. This represents execution of the company's stated commercial expansion strategy into healthcare and life sciences. While not a single discrete operational event like a major contract or partnership, the announcement of multiple material commercial wins that advance the company's strategic direction and demonstrate market traction constitutes a material operational disclosure warranting investor attention.
View raw filing on EDGAR →
8-K
Operational Other
confidence 92%
filed 2026-09-08
Item 1.01
Quantinuum entered into a material definitive agreement with the U.S. Department of Commerce on September 4, 2026, securing up to $100 million in CHIPS Act funding for trapped-ion quantum computer manufacturing R&D. Under the agreement, the Department of Commerce received 2,369,528 shares of Class A common stock, representing a material capital infusion and equity issuance that affects the company's capital structure and strategic positioning in quantum computing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-08
Item 8.01
Spyre announced positive Phase 2 SKYLINE trial topline data for SPY003 (anti-IL-23) in ulcerative colitis, demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001) and clinical remission rates of 20%, meeting all key efficacy and safety objectives. This represents a material clinical development milestone and proof-of-concept for a key pipeline asset, advancing the company's combination strategy and strengthening its IBD program.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
This disclosure announces FDA approval of Etcamah (camizestrant) in combination with CDK4/6 inhibitors for first-line HR-positive breast cancer with emergent ESR1 mutations, based on positive Phase III SERENA-6 trial results showing 56% risk reduction in disease progression or death. While this is a significant regulatory and commercial milestone for AstraZeneca's oncology portfolio, it does not fit the specific event types of earnings_release, ma_activity, or other defined categories. It is a material operational/commercial event—a major product approval—that would affect investor assessment of the company's pipeline and market position, warranting operational_other classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
Guardian Metal's admission to the FTSE AIM 50 Index effective 21 September 2026 is a significant operational and market milestone. The press release emphasizes this as "an important milestone on the journey" and reflects the company's momentum in tungsten exploration and development. While not a discrete transaction (M&A, debt issuance, or earnings event), index inclusion materially enhances the company's market profile, liquidity, and visibility to institutional investors, affecting a reasonable investor's assessment of the registrant's strategic position and market standing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
IQSTEL announced a strategic partnership with IDILIO TV to distribute premium microdrama content through its existing telecommunications operator relationships, targeting 40 million potential mobile users by Q2 2027 and 500,000 gross subscribers by year-end 2027. This is a material operational and strategic initiative leveraging the company's existing telecom infrastructure to enter a higher-margin digital content distribution business, supported by a $5 million seed round for IDILIO TV. While not a traditional M&A transaction, it represents a significant strategic pivot and new business line that would affect investor assessment of the company's growth strategy and revenue diversification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This news release announces Aris Mining's commencement of construction of a permanent bridge across the Puruni River in Guyana as an early infrastructure initiative supporting the Toroparu Gold Project. The bridge is a material operational milestone—it represents a significant capital commitment and infrastructure development that strengthens logistics access to a key project in the company's portfolio. While not a discrete event type like M&A or workforce reduction, it is clearly an operational/strategic business development that would affect a reasonable investor's assessment of project advancement and capital deployment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
GRI Bio announced positive Phase 2a translational biomarker data from its GRI-0621 (oral tazarotene) study in idiopathic pulmonary fibrosis patients, demonstrating proof-of-concept across multiple mechanistic pillars (immune rebalancing, fibrolysis, lung repair, antitussive, GI-protection) and supporting advancement toward a pivotal Phase 2b/3 adaptive study.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Inhibrx announced positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% response rate versus 26.5% for the control arm, with particularly strong results in HPV+ patients (80.0% vs 33.3%). The company plans to expand the trial and pursue an accelerated regulatory pathway.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release discloses material progress on Mayfair Gold's exploration and development program at the Fenn-Gib Project, including completion of a 2026 summer geology program (mapping 95% of outcrops, 127 grab samples, 23 condemnation drill holes totalling 6,184 metres) and advancement of South Block targets toward drill-ready status for early 2027. The company is also building a comprehensive 3D geological and geochemical model to support mine development and exploration. While not a discrete M&A, financing, or governance event, this operational milestone—advancing a development-stage gold project toward construction (targeted 2028) and production (2030)—would materially affect a reasonable investor's assessment of the registrant's progress toward its stated development strategy and timeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Liquidia announced FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder for treatment of Raynaud's phenomenon associated with systemic sclerosis. This is a regulatory milestone that accelerates development and review timelines for a clinical-stage indication, representing material progress in the company's pipeline. While not a completed M&A transaction or earnings release, this operational/regulatory achievement would affect a reasonable investor's assessment of the company's development prospects and competitive position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Milestone Pharmaceuticals announced China's NMPA approval of etripamil nasal spray for PSVT treatment, marking the first regulatory approval outside the United States. This is a material operational/regulatory milestone that triggers a $2.0 million payment and positions the company for up to $98 million in future milestone payments and royalties through its licensing partner Everest Medicines. While this is a significant product approval event, it does not fit neatly into the specific operational categories (workforce reduction, material contract, partnership) but represents a major regulatory and commercial milestone for the company's pipeline expansion.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 1.01
NextCure entered into a Ninth Amendment to its lease agreement that accelerates termination of its laboratory and office space at 8000 Virginia Manor Road, Beltsville, Maryland, effective September 1, 2026, with a one-time termination fee of approximately $0.8 million and forfeiture of a $39,000 security deposit. This is a material operational event involving the early exit from a significant facility lease (approximately 29,864 rentable square feet), though it does not fit the specific categories of M&A activity, workforce reduction, or other named operational types. The materiality is supported by the substantial termination costs and the apparent strategic decision to vacate the premises.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
This press release announces completion of the last patient visit in the NATiV3 Phase 3 clinical trial of lanifibranor for MASH treatment, with topline results expected in Q4 2026. This is a material clinical development milestone for a clinical-stage biopharmaceutical company whose lead product candidate is in pivotal Phase 3 testing. The event is operational/strategic (a key trial milestone) rather than a discrete financial, governance, or legal event, and does not fit the specific categories of earnings release, M&A, or other named types. The company has received FDA Breakthrough Therapy and Fast Track designations, and successful trial results could support regulatory submission and commercialization in 2027–2028, making this milestone material to investors assessing the company's pipeline progress and value.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 7.01
Climb Bio disclosed positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody, including a ~29-day half-life, >90% APRIL suppression, and favorable safety profile supporting every-12-week dosing. This is a material clinical development milestone for a lead pipeline asset, but does not constitute an earnings release (no financial results), M&A activity, or other specifically-defined event type. The disclosure is clearly operational—a significant clinical program update—rather than financial, governance, or legal in nature.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Aptevo announced positive interim clinical trial results for mipletamig in TP53-mutated AML patients, reporting a 93% clinical benefit rate and 79% CR/CRi rate that compares favorably to published benchmarks. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents significant progress in a lead program and addresses an unmet medical need in a difficult-to-treat patient population. While not a formal earnings release or regulatory approval, the clinical data disclosure is material to investors' assessment of the company's pipeline value and development trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-03
Item 7.01
The company disclosed a comprehensive strategic operational restructuring initiative encompassing organizational redesign, branch network optimization, and efficiency improvements, with expected pre-tax restructuring charges of $40–$45 million in Q3 2026 and anticipated annual PPNR benefits of $37–$42 million once fully implemented.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-03
EX-99.1
This is an operational update disclosing August 2026 production metrics and capacity expansion for a Bitcoin mining company. The announcement reports significant month-over-month improvements: Bitcoin production increased 55.4% to 174 BTC, total hashrate surpassed 20 EH/s (45.1% increase), and fleet efficiency improved to 16.7 J/TH. While these are operational metrics rather than a discrete event like M&A or executive change, the magnitude of the capacity expansion and production recovery would materially affect a reasonable investor's assessment of the company's operational trajectory and competitive positioning in the mining industry.
View raw filing on EDGAR →
6-K
Operational Other
confidence 72%
filed 2026-09-03
EX-99.1
Mint announced entry into a binding consulting agreement with CURRENC Capital to support issuer-sponsored tokenization of its Class A ordinary shares on Ethereum and Solana blockchains. This is a material strategic initiative involving a new capital markets infrastructure arrangement with a third-party service provider, but it does not fit neatly into standard event categories (not M&A, not debt issuance, not a discrete financing). The tokenization is designed to modernize shareholder infrastructure and investor accessibility, representing a significant operational and strategic business development that would affect investor assessment of the company's direction and shareholder engagement model.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
This press release announces the commercial launch of Steakholder Foods' Perfecta™ plant-based meat product line at retail locations across the Northeastern U.S., marking "the brand's first commercial placement on U.S. store shelves and an important milestone in the Company's growth strategy." The disclosure describes a material operational and strategic milestone—the transition from development to commercial retail distribution—supported by a partnership with KeHE Distributors. While not a discrete M&A transaction, earnings release, or other named event type, this represents a significant operational achievement that would affect a reasonable investor's assessment of the company's execution on its business strategy and market entry plans.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-03
Item 1.01
Faraday Future entered into a material consulting services agreement with AIBOT, Inc. for FCC compliance, ICTS, NDAA compliance, and U.S. localization advisory services at $25,000/month. The agreement involves related-party elements (Jerry Wang is co-founder/Executive Chairman of both entities; Max Ma and Hong Rao hold executive roles at AIBOT) and was reviewed by the Audit Committee under the company's related-party transaction policy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
This press release announces material operational and strategic progress: (1) European smart warehouse projects for Cainiao entering delivery phase with racking supply underway and completion targeted by year-end 2026; and (2) a new North America automated cold-storage project with an estimated contract value of approximately US$30 million expected to commence in September 2026. These represent significant business development milestones and material contracts for the Company's subsidiaries Jingxing HK and Shanghai Jingxing, demonstrating execution of the previously announced cooperation framework with Cainiao Group. While not fitting the specific categories of M&A activity, debt issuance, or workforce reduction, this disclosure of material contract awards and project commencement is clearly operational and strategic in nature and would affect a reasonable investor's assessment of the Company's business prospects and revenue pipeline.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
This news release announces the advancement of two exploration targets—Orion and Victory—at Collective Mining's Guayabales Project to drill-ready status, with drilling commencing immediately at Orion and scheduled for Q4-2026 at Victory. The disclosure details surface geochemistry results, structural interpretations, and planned drilling programs. This is a material operational/strategic milestone for an exploration-stage mining company, representing progress on its flagship project, but does not constitute a discrete financial event (earnings, debt, M&A) or governance matter. The company's executive chairman emphasizes the "significant prospectivity" and the decision to "push hard in exploration," indicating this is a material strategic advancement rather than routine exploration activity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
PowerBank announces award of a contract by New York Power Authority to develop and construct a 1.628 MW ground-mount solar project at SUNY Oneonta. This is a material operational/strategic business event—a significant project win with estimated construction value of $3.58 million USD and $1.4 million in federal investment tax credits. The disclosure emphasizes this as the company's "first MW-scale array" at the campus and highlights PowerBank's execution capabilities and development pipeline. While not a discrete M&A transaction, this contract award represents a material operational milestone and revenue-generating asset acquisition that would affect a reasonable investor's assessment of the company's growth trajectory and market position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-03
The filing discloses an operational update on Eightco's treasury holdings and strategic investments (OpenAI, Beast Industries, Worldcoin), along with a share repurchase program execution (25+ million shares repurchased in the past month under a $125 million program). While the press release provides portfolio composition and market commentary, it does not constitute a formal earnings release with financial results, nor does it fit neatly into other specific categories. The disclosure is material to investors assessing the company's capital allocation and investment strategy, but the event itself is primarily an operational/strategic update rather than a discrete material event like M&A, impairment, or executive change.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
Rail Vision announced its selection for MxV Rail's locomotive sensor pre-integration testing program, a real-world evaluation of its AI-powered perception technology by Class I railroads. This represents a material operational milestone—transitioning from roadmap participation to active testing with industry decision-makers—that advances the company's commercialization strategy and positions it to capture long-term demand in the North American rail automation market. The disclosure is clearly operational/strategic but does not fit a discrete named category (not M&A, not a contract announcement with specific terms, not a regulatory approval), making `operational_other` the appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Summit disclosed positive overall survival results from its partner Akeso's Phase III HARMONi-2 study of ivonescimab, a key investigational drug in Summit's pipeline. While this is clinical trial data rather than a formal earnings release or regulatory approval, the statistically significant OS benefit in a Phase III study for a lead oncology candidate is material to investors' assessment of the company's development prospects and pipeline value. The disclosure emphasizes Summit's ongoing HARMONi-7 trial and broader clinical program, making this an operational/clinical milestone rather than a financial or governance event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-03
EX-99.1
The exhibit discloses operational and commercial updates: third-quarter 2026 TCE (Time Charter Equivalent) rates for the Company's vessel fleet across different segments (LR2, MR, Handymax), and entry into three new time charter-out agreements for vessels STI Gladiator, STI Jermyn, and STI Pontiac at specified daily rates and terms. These are material operational developments affecting the Company's revenue-generating capacity and fleet deployment strategy, but do not fit discrete event categories such as earnings release, M&A, debt issuance, or workforce reduction. The disclosure is operational in nature and would affect a reasonable investor's assessment of the Company's near-term earnings and fleet utilization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
BioHarvest announces its intention to register for dual listing on the Tel Aviv Stock Exchange (TASE) alongside its existing Nasdaq listing, with trading expected to commence September 8, 2026. This is a material operational and strategic milestone—expanding market access and investor reach—but does not fit the specific event categories (it is not M&A, a debt/equity issuance, a delisting risk, or a governance appointment/departure). The dual listing is a significant business development that would affect a reasonable investor's assessment of the company's strategic positioning and liquidity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-03
EX-99.1
This press release announces a material contract win: Ruanyun Edai's consolidated VIE entered into an approximately RMB5.99 million (~US$0.88 million) contract for YeeZo platform deployment across 10 AIGC vocational training laboratories with 610 workstations. The disclosure emphasizes this as a "significant commercial milestone" moving YeeZo from launch (May 2026) to institution-scale commercial delivery, and frames it as foundational to the company's strategy to extend YeeZo to 200 universities and support its planned Formind Group transition and international expansion. While the contract value is material and the strategic significance is emphasized, this is a discrete operational/commercial event (a major customer contract) rather than a financial event (debt, equity, M&A, impairment) or governance event, making operational_other the best fit.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-03
EX-99.1
NuRAN Wireless announces the creation of NuEnergy, a wholly owned subsidiary to own and operate the company's solar, storage and hybrid power systems across its African footprint. This is a material strategic and operational restructuring that establishes a new business line combining connectivity and energy services. While not fitting a discrete event category (not M&A, not a specific governance action, not a financial obligation), the subsidiary creation and intended business model expansion represent a significant operational and strategic initiative that would affect a reasonable investor's assessment of the company's growth strategy and capital structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 7.01
uniQure announced the submission of a Biologics License Application (BLA) to the FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease treatment, along with a Marketing Authorisation Application (MAA) to the UK's MHRA. This represents a material regulatory milestone in the clinical development and commercialization pathway for a lead gene therapy candidate, supported by three-year Phase I/II data. While this is a significant operational and strategic event for the company's pipeline, it does not fit neatly into the specific event categories (e.g., it is not an earnings release, M&A activity, or a specific financial obligation), making it best classified as an operational milestone that would materially affect investor assessment of the company's progress toward commercialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
Baosheng BVI entered into an AI Business Cooperation Framework Agreement with DirectBooking Technology on August 25, 2026, to pursue long-term collaboration across media-resource integration, brand promotion, market-channel expansion, and digital operations. While the agreement is a strategic partnership rather than a discrete M&A transaction, it represents a material operational initiative to capture new commercial growth opportunities in AI. The framework agreement itself does not commit to specific projects or revenue generation, but the strategic intent and complementary capabilities (Baosheng's media operations and DirectBooking's technology infrastructure) constitute a material business development event that would affect a reasonable investor's assessment of the company's growth strategy and market positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
The filing discloses receipt of $6.5 million in new orders for Hyperboloid connectors supporting the APKWS defense program, with backlog tripled to over $45 million year-over-year. This represents a material operational and commercial milestone for a defense contractor, though it does not fit neatly into earnings_release (no financial results disclosed), ma_activity, or other specific categories. The press release emphasizes unprecedented demand and production ramp-up, making this a significant operational development material to investors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-02
EX-99.1
This press release announces a significant Design Win with a tier-1 cloud-based cyber security customer for a 5G-enabled Edge Networking device, with projected revenues exceeding $5 million annually at full ramp-up and potential for additional higher-end platforms. While this is a material operational/commercial milestone reflecting strong business momentum (the company's eighth Design Win in 2026, matching all of 2025), it does not fit the specific event-type categories of earnings_release, ma_activity, or other defined types. The disclosure is clearly operational and material to investor assessment of the company's growth trajectory and customer wins, warranting operational_other classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-02
EX-99.1
This press release announces a strategic deployment agreement with one of Israel's three largest defense companies for QTREX's AME technology, including exclusivity provisions and a phased commercial pathway with aggregate revenue potential in the tens of millions of dollars. While the partner's identity is confidential, the disclosure describes a material operational and commercial milestone—immediate system deployment, recurring consumables revenue, and structured procurement phases—that represents a significant business development for the company's core AME platform in the defense/aerospace sector. This is a material operational/strategic event rather than a discrete financial event (no debt, equity issuance, or M&A transaction is disclosed), and it does not fit the specific categories of ma_activity (no acquisition or merger), earnings_release (no financial results), or other named types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-02
EX-99.1
This media release discloses an unplanned outage at Algoma's Lake Superior Power generating facility that has disrupted steelmaking operations. While the company has resumed EAF production under interim arrangements since August 29, 2026, the disclosure addresses a material operational disruption and ongoing efforts to restore full generating capacity through turbine repair or replacement. This is a significant operational event affecting production and shipments, but does not fit the specific categories of workforce reduction, material litigation, debt covenant breach, or other named event types—making it an operational_other event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 7.01
The disclosure reports initial gold assay results from the 2026 surface diamond drilling program at the Lucky Shot Project and underground exploration development progress, including discovery of two previously unmodeled KM-style mineralized vein structures. This is a material operational/exploration milestone for an exploration-stage gold company, disclosing significant drill intercepts (2.45 meters grading 86.05 g/t Au) and new mineralized structures that advance the company's geologic model and exploration strategy, but does not constitute earnings, M&A activity, or other specifically-named event types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-02
Item 8.01
Ultragenyx disclosed failure of the Phase 3 Aspire study for apazunersen (GTX-102) to meet its primary and key secondary endpoints in Angelman syndrome treatment. The company announced it will evaluate the program's disposition and implement significant expense reductions. This is a material operational/clinical event affecting the company's pipeline and future operations, but does not fit the specific categories of earnings release, material impairment, or workforce reduction—it is a clinical development setback with strategic implications.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 1.01
Cogent Biosciences entered into a Commercial Supply Agreement with Hovione on September 1, 2026, to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. This is a material supply/manufacturing contract for the Company's product, with a five-year initial term and automatic renewals. While Item 1.01 typically covers M&A activity, this is a supply agreement rather than an acquisition, disposition, or change of control; it is a material operational/commercial contract that does not fit the specific M&A definition but is clearly material to the Company's business operations and product supply chain.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-02
Item 7.01
Microsoft disclosed a material reorganization of its reportable segments and investor metrics effective FY27, transitioning from three segments (Productivity and Business Processes, Intelligent Cloud, More Personal Computing) to two segments (Agents and Infra, Devices and Consumer). This restructuring reflects how the company now manages operations and allocates resources in response to AI's impact on the business, and includes comprehensive restatement of historical financial data under the new structure. While this is a significant operational and strategic realignment affecting how investors will assess the company's performance going forward, it does not fit the specific categories of M&A activity, impairment, debt issuance, or other named event types—it is a structural business reorganization disclosed under Regulation FD.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
This press release announces a positive interim development in Can-Fite's pivotal Phase III trial of Namodenoson for hepatocellular carcinoma—specifically, longer-than-anticipated overall survival in the blinded study population and the company's decision to advance the timing of the planned interim analysis. While the company emphasizes that no treatment efficacy conclusions can yet be drawn (the study remains blinded), the announcement of improved survival metrics and acceleration of interim analysis represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the drug candidate's development trajectory and commercial prospects. This is not a discrete earnings release, M&A event, or executive change, but rather a material clinical-development milestone.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
Purple Biotech announced a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use for its CAPTN-3 platform. This is a material intellectual property milestone that strengthens the company's patent estate and competitive position in its core immunotherapy platform. While not a discrete event type like M&A or earnings, the patent allowance is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's IP protection and platform defensibility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
This press release announces a strategic partnership between Eco Wave Power U.S. and AI engineering GmbH to develop a Digital Twin platform for wave energy systems. The agreement represents a material operational and strategic development—combining advanced simulation, machine learning, and real-world data to optimize the company's proprietary technology and support global scalability. While not a discrete M&A transaction, debt issuance, or other named event type, it is clearly a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's technology roadmap and competitive positioning.
View raw filing on EDGAR →